M&A | Partnerships

The companies will work together for development and commercialization of Novosis rhBMP-2 bone growth materials and other solutions for the U.S. and Canada.

The company's multi-year supply agreement with Arthrex addresses advanced synthetic bone graft materials.

The amended agreement reduces the closing payment to $50 million (plus $50 million deposited into escrow last year) from the original $315 million.

Legacy DBM expands and complements the Orthofix line of biologic solutions for spine and orthopedic surgical applications.

ORHub will enter the medical device market with biologics to regenerate cartilage and address degenerative disc disease and osteoarthritis.

StemCART is a preclinical Advanced Therapy Medical Product intended for the treatment of cartilage damage in patients worldwide.

The move will expand Isto's portfolio of procedure-specific allografts for spine, orthopedic and sports medicine applications.

The decision follows FDA's recent premarket approval of CartiHeal's Agili-C implant for the treatment of osteoarthritis.

genex Bone Graft Substitute has been upgraded with a new closed-mixing system and a comprehensive set of delivery options for U.S. market.

Bimini's Autopose family of products are designed for the harvesting and micro-fragmentation of adipose tissue.